Patents by Inventor W. Jerry Easterling

W. Jerry Easterling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7851431
    Abstract: The present invention relates to methods and compositions for the treatment and/or prevention of actinic keratoses comprising a calcium channel blocking compound.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: December 14, 2010
    Assignee: Prescription Dispensing Laboratories
    Inventors: W. Jerry Easterling, Michael J. Bordovsky
  • Publication number: 20040253300
    Abstract: The invention is of a non-invasive, topical medicament and associated methodology for use thereof, through the use of which existing scars may be effectively, cost effectively, and painlessly treated. One or more calcium channel blocker agents serve as the primary active ingredient of the present compositions and transdermal penetration agents or carriers are included to facilitate topical delivery of the active ingredient(s) to the intended, sub-dermal treatment site.
    Type: Application
    Filed: August 13, 2004
    Publication date: December 16, 2004
    Inventor: W. Jerry Easterling
  • Publication number: 20040197368
    Abstract: The invention is of the design for, and a method of use of, an improved surgical stent. The stent is coated with a slow-release calcium channel blocker agent which interrupts the accumulation or deposition of fibrotic tissue as occurs in the process of re-occlusion of the vessel, orifice, or conduit as attends the use of conventional stents.
    Type: Application
    Filed: April 27, 2004
    Publication date: October 7, 2004
    Inventor: W. Jerry Easterling
  • Publication number: 20040170674
    Abstract: The invention is of a novel, noninvasive method for treating hemangiomas involving the topical application of one or more calcium channel blocker agents suspended in one or more carriers with penetration enhancing agent's two effect transdermal delivery of the calcium channel blocker agent(s). Periodic, topical application of the medicaments taught here in will effect, usually within a few months, and involution of treated hemangiomas with minimized residual cosmetic blemishes after involution.
    Type: Application
    Filed: April 27, 2004
    Publication date: September 2, 2004
    Inventor: W. Jerry Easterling
  • Publication number: 20040170675
    Abstract: The invention is of a novel, noninvasive method for treating cellulite involving the topical application of one or more calcium channel blocker agents suspended in one or more carriers with penetration enhancing agent's to effect transdermal delivery of the calcium channel blocker agent(s). Periodic, topical application of the medicaments taught here in will effect, usually within a few months, a substantial reduction or elimination of palpable cellulite.
    Type: Application
    Filed: April 27, 2004
    Publication date: September 2, 2004
    Inventor: W. Jerry Easterling
  • Publication number: 20040171684
    Abstract: The invention is of an improved to topical medicament and associated methodology for use thereof, through the use of which aberrant fibrotic tissue manifestations involving scarring or sub-dermal plaque formations or accumulations may be effectively, cost effectively, and painlessly treated, one or more calcium channel blocker agents serve as the primary active ingredient of the present compositions and transdermal penetration agents or carriers are included to facilitate topical delivery of the active ingredient(s) to the intended, sub-dermal treatment site.
    Type: Application
    Filed: April 27, 2004
    Publication date: September 2, 2004
    Inventor: W. Jerry Easterling
  • Patent number: 6627663
    Abstract: The invention is of a noninvasive method for treating hemangiomas involving the topical application of verapamil suspended in a carrier through which penetration of verapamil is enhanced.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: September 30, 2003
    Inventor: W. Jerry Easterling
  • Patent number: 6627209
    Abstract: The invention is of the design for, and a method of use of, an improved surgical stent. The stent is coated with a slow-release calcium channel blocker agent which interrupts the accumulation or deposition of fibrotic tissue as occurs in the process of re-occlusion of the vessel, orifice, or conduit as attends the use of conventional stents.
    Type: Grant
    Filed: April 20, 2001
    Date of Patent: September 30, 2003
    Inventor: W. Jerry Easterling
  • Publication number: 20030162769
    Abstract: The invention is of a medicament and associated treatment involving the use of such medicament for the treatment of vulvodynia. The medicament is in the dosage form of a vaginal suppository, and the primary active ingredient is a calcium antagonist—Diltiazem Hydrochloride in the preferred embodiment.
    Type: Application
    Filed: February 26, 2002
    Publication date: August 28, 2003
    Inventor: W. Jerry Easterling
  • Patent number: 6525100
    Abstract: The invention is of a topical medicament and associated methodology for use thereof, through the use of which Peyronie's disease may be effectively, cost effectively, and painlessly treated. The primary active ingredient is a calmodulin blocker, the preferred such ingredient being trifluroperizine.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: February 25, 2003
    Inventors: W. Jerry Easterling, William P. Fitch, III
  • Publication number: 20020160995
    Abstract: The invention is of a non-invasive, topical medicament and associated methodology for use thereof, through the use of which existing scars may be effectively, cost effectively, and painlessly treated. One or more calcium channel blocker agents serve as the primary active ingredient of the present compositions and transdermal penetration agents or carriers are included to facilitate topical delivery of the active ingredient(s) to the intended, sub-dermal treatment site.
    Type: Application
    Filed: October 24, 2001
    Publication date: October 31, 2002
    Inventor: W. Jerry Easterling
  • Publication number: 20020156065
    Abstract: The invention is of a topical medicament and associated methodology for use thereof, through the use of which sub-dermal, aberrant fibrotic tissue masses are “remodeled” through the topical, non-invasive, transdermal application of the calcium channel blocker diltiazem.
    Type: Application
    Filed: February 8, 2002
    Publication date: October 24, 2002
    Inventor: W. Jerry Easterling
  • Publication number: 20020151537
    Abstract: The invention is of a topical medicament and associated methodology for use thereof, through the use of which fibrosis of the elastic tissues and muscles of the human penis is reduced, thereby improving erectile function and/or reversing erectile dysfunction. One or more calcium channel blocker agents serve as the primary active ingredient of the present compositions, with carrier agents facilitating non-invasive transdermal delivery of the calcium channel blocker(s) to fibrotic tissues of the penis.
    Type: Application
    Filed: October 24, 2001
    Publication date: October 17, 2002
    Inventor: W. Jerry Easterling
  • Publication number: 20020028234
    Abstract: The invention is of a novel, noninvasive method for treating hemangiomas involving the topical application of one or more calcium channel blocker agents suspended in one or more carriers with penetration enhancing agent's to effect transdermal delivery of the calcium channel blocker agent(s). Periodic, topical application of the medicaments taught here in will effect, usually within a few months, and involution of treated hemangiomas with minimized residual cosmetic blemishes after involution.
    Type: Application
    Filed: April 20, 2001
    Publication date: March 7, 2002
    Inventor: W. Jerry Easterling
  • Patent number: 6353028
    Abstract: The invention is of a topical medicament and associated methodology for use thereof, through the use of which fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations or fibrosis of muscle tissue may be effectively, cost effectively, and painlessly treated. One or more calcium channel blocker agents serve as the primary active ingredient of the present compositions, with carrier agents facilitating non-invasive transdermal delivery of the calcium channel blocker(s) to subdermal disease sites.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: March 5, 2002
    Inventor: W. Jerry Easterling
  • Publication number: 20020022664
    Abstract: The invention is of an improved to topical medicament and associated methodology for use thereof, through the use of which aberrant fibrotic tissue manifestations involving scarring or sub-dermal plaque formations or accumulations may be effectively, cost effectively, and painlessly treated. One or more calcium channel blocker agents serve as the primary active ingredient of the present compositions and transdermal penetration agents or carriers are included to facilitate topical delivery of the active ingredient(s) to the intended, sub-dermal treatment site.
    Type: Application
    Filed: April 20, 2001
    Publication date: February 21, 2002
    Inventor: W. Jerry Easterling
  • Publication number: 20020019445
    Abstract: The invention is of a novel, noninvasive method for treating cellulite involving the topical application of one or more calcium channel blocker agents suspended in one or more carriers with penetration enhancing agent's to effect transdermal delivery of the calcium channel blocker agent(s). Periodic, topical application of the medicaments taught here in will effect, usually within a few months, a substantial reduction or elimination of palpable cellulite.
    Type: Application
    Filed: April 20, 2001
    Publication date: February 14, 2002
    Inventor: W. Jerry Easterling
  • Publication number: 20020004678
    Abstract: The invention is of the design for, and a method of use of, an improved surgical stent. The stent is coated with a slow-release calcium channel blocker agent which interrupts the accumulation or deposition of fibrotic tissue as occurs in the process of re-occlusion of the vessel, orifice, or conduit as attends the use of conventional stents.
    Type: Application
    Filed: April 20, 2001
    Publication date: January 10, 2002
    Inventor: W. Jerry Easterling
  • Patent number: 6031005
    Abstract: The invention is of a topical medicament and associated methodology for use thereof, such that Peyronie's disease may be effectively, cost effectively, and painlessly treated. The primary active ingredient is a calcium channel blocker, the preferred such ingredient being verapamil.
    Type: Grant
    Filed: August 3, 1998
    Date of Patent: February 29, 2000
    Inventor: W. Jerry Easterling